PROTEKT 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea

被引:42
作者
Inoue, M
Lee, NY
Hong, SW
Lee, K
Felmingham, D
机构
[1] Kitasato Univ, Sch Med, Dept Microbiol, Sagamihara, Kanagawa 2288555, Japan
[2] Sungkyunkwan Univ, Sch Med, Seoul, South Korea
[3] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[4] Yonsei Univ, Coll Med, Seoul, South Korea
[5] GR Micro Ltd, London, England
关键词
Far East; PROTEKT; respiratory tract infections; antibacterial susceptibility;
D O I
10.1016/j.ijantimicag.2003.07.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A multicentre surveillance study performed in the Far East during 1999-2000 investigated the in vitro activity of >20 antibacterials against common respiratory pathogens. In Hong Kong, Japan, and South Korea, 57.1, 44.5 and 71.5% Streptococcus pneumoniae were penicillin-resistant and 71.4, 77.9 and 87.6% were erythromycin-resistant, respectively. Overall, >90% of penicillin-resistant strains were also macrolide-resistant. All strains were susceptible to telithromycin. Fluoroquinolone-resistant isolates in Japan (1.3%), Hong Kong (14.3%) and South Korea (2.9%) were mostly co-resistant to penicillin, macrolides and tetracycline. Beta-lactamase production by Haemophilus influenzae isolates was 8.5% in Japan, 17.1% in Hong Kong and 64.7% in strains from South Korea. A single (0.27%) BLNAR isolate was obtained in Japan. There was no fluoroquinolone resistance. Moraxella catarrhalis was inhibited by telithromycin at less than or equal to0.5 mg/l and remained susceptible to macrolides, fluoroquinolones and amoxicillin-clavulanate. Resistance to antibacterials, particularly penicillin and macrolides, has reached high but stable levels in the Far East and the presence of multiply-resistant pneumococci is well established. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:44 / 51
页数:8
相关论文
共 24 条
[1]  
[Anonymous], 2002, M100S12 NCCLS
[2]  
Balfour JAB, 2001, DRUGS, V61, P815
[3]   Pneumococcal resistance to beta-lactam antibiotics: A global geographic overview [J].
Baquero, F .
MICROBIAL DRUG RESISTANCE, 1995, 1 (02) :115-120
[4]  
Bartlett RC., 1974, MED MICROBIOLOGY, P24
[5]   Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy [J].
Dagan, R ;
Klugman, KP ;
Craig, WA ;
Baquero, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (02) :129-140
[6]   Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study [J].
Farrell, DJ ;
Morrissey, I ;
Bakker, S ;
Felmingham, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :39-47
[7]   Detection of macrolide resistance mechanisms in Streptococcus pneumonide and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization [J].
Farrell, DJ ;
Morrissey, I ;
Bakker, S ;
Felmingham, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :541-544
[8]   ANTIBIOTIC-RESISTANCE - DO WE NEED NEW THERAPEUTIC APPROACHES [J].
FELMINGHAM, D .
CHEST, 1995, 108 (02) :S70-S78
[9]   The Alexander Project 1996-1997:: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections [J].
Felmingham, D ;
Grüneberg, RN .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) :191-203
[10]   The need for antimicrobial resistance surveillance [J].
Felmingham, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :1-7